您当前所在的位置:首页 > 产品中心 > 产品详细信息
26171-23-3 分子结构
点击图片或这里关闭

2-[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetic acid

ChemBase编号:383
分子式:C15H15NO3
平均质量:257.2845
单一同位素质量:257.10519335
SMILES和InChIs

SMILES:
O=C(c1n(c(cc1)CC(=O)O)C)c1ccc(cc1)C
Canonical SMILES:
OC(=O)Cc1ccc(n1C)C(=O)c1ccc(cc1)C
InChI:
InChI=1S/C15H15NO3/c1-10-3-5-11(6-4-10)15(19)13-8-7-12(16(13)2)9-14(17)18/h3-8H,9H2,1-2H3,(H,17,18)
InChIKey:
UPSPUYADGBWSHF-UHFFFAOYSA-N

引用这个纪录

CBID:383 http://www.chembase.cn/molecule-383.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
2-[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetic acid
IUPAC传统名
[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid
tolmetin
商标名
Tolectin
Tolectin DS
别名
1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic Acid Sodium Dihydrate
1-Methyl-5-p-toluoylpyrrole-2-acetic Acid Sodium Dihydrate
5-[(p-Tolyl)carbonyl]-1-methylpyrrole-2-acetic Acid Sodium Dihydrate
McN 2559-21-98
Tolectin
Tolmene
Tolmetin Sodium Salt Dihydrate
Tolmetine [INN-French]
Tolmetino [INN-Spanish]
Tolmetinum [INN-Latin]
Tolmetina [DCIT]
Tolmetin Sodium
Tolmetin
1-Methyl-5-p-toluoylpyrrole-2-acetic acid
2-(1-Methyl-5-(4-Methylbenzoyl)-1H-pyrrol-2-yl)acetic acid
CAS号
26171-23-3
64490-92-2
MDL号
MFCD00599595
PubChem SID
46507060
160963846
PubChem CID
5509
ATC码
M02AA21
M01AB03
CHEMBL
1020
Chemspider ID
5308
DrugBank ID
DB00500
KEGG ID
D02355
美国药典/FDA物质标识码
D8K2JPN18B
维基百科标题
Tolmetin
Medline Plus
a681033

理论计算性质

理论计算性质

JChem ALOGPS 2.1
Acid pKa 3.9581683  质子受体
质子供体 LogD (pH = 5.5) 1.1776481 
LogD (pH = 7.4) -0.4552389  Log P 2.727331 
摩尔折射率 72.3928 cm3 极化性 27.405663 Å3
极化表面积 59.3 Å2 可自由旋转的化学键
里宾斯基五规则 true 
Log P 2.81  LOG S -3.29 
溶解度 1.31e-01 g/l 

分子性质

分子性质

理化性质 安全信息 药理学性质 产品相关信息 生物活性(PubChem)
溶解度
222 mg/L expand 查看数据来源
Water expand 查看数据来源
外观
White Solid expand 查看数据来源
熔点
>288°C (dec.) expand 查看数据来源
疏水性(logP)
2.6 expand 查看数据来源
保存条件
-20°C Freezer expand 查看数据来源
保存注意事项
IRRITANT expand 查看数据来源
MSDS下载
下载链接 expand 查看数据来源
下载链接 expand 查看数据来源
TSCA收录
false expand 查看数据来源
给药途径
oral expand 查看数据来源
半衰期
1-2 hours, next phase up to 5 hours expand 查看数据来源
纯度
95+% expand 查看数据来源
97% expand 查看数据来源
质检报告
下载链接 expand 查看数据来源

详细说明

详细说明

DrugBank DrugBank Wikipedia Wikipedia TRC TRC
DrugBank -  DB00500 external link
Item Information
Drug Groups approved
Description A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. [PubChem]
Indication For the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, including the treatment of acute flares long-term management. Also for treatment of juvenile rheumatoid arthritis.
Pharmacology Tolmetin is a nonsteroidal anti-inflammatory agent. Studies in animals have shown tolmetin to possess anti-inflammatory, analgesic and antipyretic activity. In the rat, tolmetin prevents the development of experimentally induced polyarthritis and also decreases established inflammation. In patients with either rheumatoid arthritis or osteaoarthritis, tolmetin is as effective as aspirin and indomethacin in controlling disease activity, but the frequency of the milder gastrointestinal adverse effects and tinnitus was less than in aspirin-treated patients, and the incidence of central nervous system adverse effects was less than in indomethacin-treated patients. In patients with juvenile rheumatoid arthritis, tolmetin is as effective as aspirin in controlling disease activity, with a similar incidence of adverse reactions. tolmetin has produced additional therapeutic benefit when added to a regimen of gold salts and, to a lesser extent, with corticosteroids. Tolmetin should not be used in conjunction with salicylates since greater benefit from the combination is not likely, but the potential for adverse reactions is increased.
Toxicity Symptoms of overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain.
Affected Organisms
Humans and other mammals
Biotransformation Essentially all of the administered dose is recovered in the urine in 24 hours either as an inactive oxidative metabolite or as conjugates of tolmetin.
Absorption Rapidly and almost completely absorbed with peak plasma levels being reached within 30-60 minutes after an oral therapeutic dose.
Half Life Biphasic elimination from the plasma consisting of a rapid phase with a half-life of one to 2 hours followed by a slower phase with a half-life of about 5 hours.
External Links
Wikipedia
RxList
PDRhealth
Drugs.com
Toronto Research Chemicals -  T535350 external link
Anti-inflammatory.

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • Carson, et al.: J. Med. Chem., 14, 646 (1971)
  • Wong, S., et al.: J. Pharmacol. Exp. Ther., 185, 127 (1971)
  • Brogden, R.N., et al.: Drugs, 15, 429 (1971)
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle